John McLaughlin resigned as a director of Seattle Genetics Inc. to focus on his responsibilities as president and CEO of PDL BioPharma Inc., effective Dec. 16.
Following McLaughlin's resignation, Daniel Welch was appointed to the board's audit committee.
Welch is an independent director of Seattle Genetics.